14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
SYK vs TMO: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Stryker Corporation (SYK) is the stronger overall head-to-head candidate over Thermo Fisher Scientific, Inc. (TMO) in the Tradestie Institutional Equity Comparison Engine, winning 4–6 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). SYK carries a Unified Composite Score of 46.5/100 (HOLD) at $310.79 (19.0x Forward P/E, 24.0% operating margin), whereas TMO carries 48.6/100 (HOLD) at $693.73 (25.2x Forward P/E, 19.1% operating margin).
Composite vs. Pillar Nuance: While TMO currently prints a higher short-term Unified Composite Score (48.6/100 HOLD vs. SYK 46.5/100 HOLD), SYK captures the overall institutional head-to-head verdict (4–6 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (24.0% vs. 19.1% operating margin) and revenue trajectory (+7.6% vs. +9.1% YoY).
Competes within the Medical Devices value chain with $118.9B market capitalization and 24.0% operating margin.
OpEx & R&D Reinvestment41.7% of Rev ($11.0B)
90D Engineering Disclosures0 Published · Surgical Robotics
TMO Moat ProfileHigh Switching-Cost Moat
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $259.2B market capitalization and 19.1% operating margin.
OpEx & R&D Reinvestment22.2% of Rev ($10.5B)
90D Engineering Disclosures0 Published · Spatial Genomics
Investor FAQ SYK vs TMO Key Questions & Quantitative Answers
As of Nov 16, 2026, Stryker Corporation (SYK) is the stronger overall head-to-head candidate over Thermo Fisher Scientific, Inc. (TMO) in the Tradestie Institutional Equity Comparison Engine, winning 4–6 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). SYK carries a Unified Composite Score of 46.5/100 (HOLD) at $310.79 (19.0x Forward P/E, 24.0% operating margin), whereas TMO carries 48.6/100 (HOLD) at $693.73 (25.2x Forward P/E, 19.1% operating margin). Composite vs. Pillar Nuance: While TMO currently prints a higher short-term Unified Composite Score (48.6/100 HOLD vs. SYK 46.5/100 HOLD), SYK captures the overall institutional head-to-head verdict (4–6 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (24.0% vs. 19.1% operating margin) and revenue trajectory (+7.6% vs. +9.1% YoY).
TMO leads the Growth & Scale pillar: SYK posts +7.6% YoY revenue growth and -11.7% YoY earnings growth on $26.3B TTM revenue (65.7% gross margin, 24.0% operating margin), compared with TMO at +9.1% YoY revenue growth and +8.7% YoY earnings growth on $47.4B TTM revenue (41.3% gross margin, 19.1% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), SYK cumulative revenue shifted +84.7% while TMO shifted +82.9%. In operating R&D and SG&A reinvestment, SYK deploys 41.7% of Rev ($11.0B) (0 90-day corporate R&D disclosures) versus 22.2% of Rev ($10.5B) (0 disclosures) for TMO.
SYK screens cheaper on headline valuation multiples. SYK trades at 19.0x Forward P/E, 33.3x Trailing P/E, 1.54x PEG, and 5.0x EV/Revenue (17.4% FCF margin), whereas TMO trades at 25.2x Forward P/E, 36.9x Trailing P/E, 2.08x PEG, and 6.2x EV/Revenue (16.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SYK (16.0% ROE) versus TMO (13.4% ROE) capital efficiency.
In options market volatility and institutional positioning, SYK carries 28.1% implied volatility (5th %ile, Compressed (<25th %ile)), a 0.30x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (0.22β · 50% Vol realized risk). By comparison, TMO carries 35.2% implied volatility (4th %ile, Compressed (<25th %ile)), a 0.57x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.61β · 31% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.